June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses. Upfront Payment $7.0MM Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study Milestone 2.0 $88.5MM […]
BiPar Sciences (Brisbane, CA) a clinical-stage biopharmaceutical company focused on DNA repair using Poly ADP-Ribose Polymerase (PARP) inhibitors, closed a $16M Series C financing. Participants include Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners.